The Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
from Latest articles from Cancer Therapy Advisor News http://bit.ly/2AfpUsu
from Latest articles from Cancer Therapy Advisor News http://bit.ly/2AfpUsu